Activating mutations of NFE2L2 and inactivating mutations of KEAP1 are found in approximately 6% and 4% of HCC, and confer to cancer cells an advantage of resistance to oxidative stress through the inhibition of KEAP1-mediated degradation of NRF2 [26]. The gene discussed is KEAP1; the disease is hepatocellular carcinoma.